Researchers tested the accuracy of five AI models using 500 everyday math prompts. The results show that there is roughly a ...

England have been drawn into Group L alongside Croatia, Ghana and Panama at the 2026 World Cup - here's who they could face in the knockout stages England would only qualify for the Round of 32 if ...

If you have been wondering whether Exact Sciences is still worth buying after its huge run, you are not alone. This breakdown is designed to help you decide if the current price makes sense. The stock ...

Pour one out for the ancient MetroCard and its equally old cousin, the PATH SmartLink card. The beginning of the end for these longtime ways to pay fares on the bi-state PATH system came Thursday when ...

JEE Main 2026: Preparing for JEE Main 2026 becomes far more effective when students solve high-quality sample papers for all three subjects Mathematics, Physics, and Chemistry. To support aspirants, ...

Abbott made one of the biggest deals in recent medtech history last week when it announced its plan to acquire Exact Sciences — maker of colon cancer screening test Cologuard — for $23 billion.

The SOF International Mathematics Olympiad (IMO) is an annual math competition for students in grades 1 through 12. It's run by SOF to test students' math and logic skills. This Olympiad's syllabus is ...

A new demo of Google’s Nano Banana Pro has set social media buzzing, thanks to a viral post showcasing just how precisely the tool can read and recreate handwritten work. The now-popular image shared ...

Exact agreed to be bought out by Abbott Labs for $105 per share. The buyout is at a hefty premium to the share price at the start of the week, but still well below Exact's 2021 highs. Shareholders ...

Gift Article 10 Remaining As a subscriber, you have 10 articles to gift each month. Gifting allows recipients to access the article for free. Abbott Laboratories agreed to acquire cancer-screening ...

(Reuters) -Abbott will buy cancer test maker Exact Sciences in a deal valued at up to $23 billion, including debt, marking one of its largest purchases in nearly a decade and a bold entry into the ...

The cancer diagnostics specialist might, just might, be on the verge of selling itself. The apparent would-be buyer is a top name in the U.S. pharmaceutical industry. A strategic investor is ...